Myelodysplastic Syndromes (MDS)

Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer

Original Publication Date
Article Source
External Web Content
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics…

Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study

Original Publication Date
Article Source
External Web Content
Abstract Introduction Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result…

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study 

Original Publication Date
Article Source
External Web Content
Abstract Purpose: To evaluate the efficacy and safety of the cluster of differentiation 47-targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE…

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are clonal myeloid neoplasms shaped by genetic lesions and immune dysregulation, both of which contribute to disease progression and poor outcomes. Existing prognostic systems, such as IPSS-R and IPSS-M, do not incorporate immune alterations. We assessed the biological and clinical relevance of an immune dysfunction signature (IDS) across multi-center MDS and CMML cohorts. IDS scores, derived from bulk transcriptomic data, were significantly associated with inferior leukemia-free and overall survival.

Fueling Your Journey: Nutrition Support for Aplastic Anemia, MDS, and PNH

Thumbnail for video Watch Now

Topic(s)
Aplastic Anemia
Living Well with Bone Marrow Failure
Managing Your Treatment
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this webinar, Sondos Khattab, Registered Dietitian, will discuss practical tips for managing treatment-related challenges, food safety, and making informed nutrition choices to support overall health. Questions can be submitted in advance at help@aamds.org.

Inherited Disorders

Thumbnail for video Watch Now

Topic(s)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Presenter(s)
Sioban Keel, MD
Dr. Sioban Keel discusses inherited disorders, genetic testing, how these disorders are diagnosed, and their impact on treatment decisions and care.

MDS Transplant

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Naveed Ali, MD
Dr. Naveed Ali provides an overview of transplantation for myelodysplastic syndromes (MDS), when a transplant may be recommended, the transplant process, potential risks and benefits, recovery, and long-term follow-up.
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.